-
Something wrong with this record ?
The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients
A. Olšerová, P. Janský, H. Magerová, T. Šrámková, P. Kešnerová, S. Kmetonyová, V. Šulc, H. Halmová, M. Šrámek, I. Šarbochová, J. Paulasová-Schwabová, K. Benešová, J. Macek, V. Maťoška, A. Tomek
Language English Country United States
Document type Journal Article, Multicenter Study
- MeSH
- Antithrombins * adverse effects blood pharmacokinetics administration & dosage MeSH
- Dabigatran * adverse effects pharmacokinetics blood administration & dosage MeSH
- Atrial Fibrillation drug therapy genetics complications blood MeSH
- Ischemic Stroke * prevention & control genetics blood MeSH
- Polymorphism, Single Nucleotide MeSH
- Carboxylic Ester Hydrolases * genetics blood MeSH
- Hemorrhage * chemically induced blood MeSH
- Middle Aged MeSH
- Humans MeSH
- ATP Binding Cassette Transporter, Subfamily B * genetics MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
BACKGROUND: Dabigatran directly inhibits thrombin and is used in primary and secondary stroke prevention in individuals with nonvalvular atrial fibrillation. The prodrug dabigatran etexilate is absorbed by enteral P-glycoprotein (ABCB1) and then activated by hepatic and intestinal carboxylesterases (CES1) to produce active metabolites. Variations in dabigatran metabolism because of genetics may affect concentration levels and clinical outcomes. STUDY QUESTION: We conducted a study to assess how polymorphisms in the CES1 (rs2244613) and ABCB1 (rs4148738) genes affect the through plasma level (c min ) of dabigatran and its correlation to clinical outcomes. STUDY DESIGN: Retrospective multicentric study of consecutive patients on dabigatran therapy. Examination of CES1 rs2244613 and ABCB1 rs4148738 polymorphisms, c min 12 hours after administration, clinical follow-up (ischemic stroke, major or clinically relevant hemorrhage, myocardial infarction, other thromboembolism, and death). MEASURES AND OUTCOMES: A total of 432 patients received treatment for an average of 19.78 months (SD of 20.165). The sex distribution of the patients was 56.5% male, and the average age was 67.56 years (SD of 14.7). The ABCB1 variant genotype was present in 67.8% of patients, whereas 37.5% carried the CES1 polymorphism. RESULTS: Compared with wild-type patients, patients with the CES1 variant had significantly lower dabigatran plasma levels (with a mean difference of 16.986; 95% confidence interval, 5.794-28.178 ng/mL, P = 0.003). We also found a significant risk of major bleeding in patients carrying the ABCB1 rs4148738 allele (hazard ratio = 1.99, confidence interval 95% 1.10 to 3.59, P = 0.024). CONCLUSIONS: The CES1 variant genotype rs2244613 is closely linked with reduced c min of dabigatran. Carriers of the ABCB1 rs4148738 polymorphism exhibit a tendency toward higher plasma levels of dabigatran, which leads to a significantly increased risk of bleeding.
Department of Neurology Military University Hospital Prague Prague Czech Republic
Laboratory of Molecular Diagnostics Hospital Na Homolce Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019937
- 003
- CZ-PrNML
- 005
- 20241024110854.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MJT.0000000000001710 $2 doi
- 035 __
- $a (PubMed)38525959
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Olšerová, Anna $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 245 14
- $a The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients / $c A. Olšerová, P. Janský, H. Magerová, T. Šrámková, P. Kešnerová, S. Kmetonyová, V. Šulc, H. Halmová, M. Šrámek, I. Šarbochová, J. Paulasová-Schwabová, K. Benešová, J. Macek, V. Maťoška, A. Tomek
- 520 9_
- $a BACKGROUND: Dabigatran directly inhibits thrombin and is used in primary and secondary stroke prevention in individuals with nonvalvular atrial fibrillation. The prodrug dabigatran etexilate is absorbed by enteral P-glycoprotein (ABCB1) and then activated by hepatic and intestinal carboxylesterases (CES1) to produce active metabolites. Variations in dabigatran metabolism because of genetics may affect concentration levels and clinical outcomes. STUDY QUESTION: We conducted a study to assess how polymorphisms in the CES1 (rs2244613) and ABCB1 (rs4148738) genes affect the through plasma level (c min ) of dabigatran and its correlation to clinical outcomes. STUDY DESIGN: Retrospective multicentric study of consecutive patients on dabigatran therapy. Examination of CES1 rs2244613 and ABCB1 rs4148738 polymorphisms, c min 12 hours after administration, clinical follow-up (ischemic stroke, major or clinically relevant hemorrhage, myocardial infarction, other thromboembolism, and death). MEASURES AND OUTCOMES: A total of 432 patients received treatment for an average of 19.78 months (SD of 20.165). The sex distribution of the patients was 56.5% male, and the average age was 67.56 years (SD of 14.7). The ABCB1 variant genotype was present in 67.8% of patients, whereas 37.5% carried the CES1 polymorphism. RESULTS: Compared with wild-type patients, patients with the CES1 variant had significantly lower dabigatran plasma levels (with a mean difference of 16.986; 95% confidence interval, 5.794-28.178 ng/mL, P = 0.003). We also found a significant risk of major bleeding in patients carrying the ABCB1 rs4148738 allele (hazard ratio = 1.99, confidence interval 95% 1.10 to 3.59, P = 0.024). CONCLUSIONS: The CES1 variant genotype rs2244613 is closely linked with reduced c min of dabigatran. Carriers of the ABCB1 rs4148738 polymorphism exhibit a tendency toward higher plasma levels of dabigatran, which leads to a significantly increased risk of bleeding.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a dabigatran $x škodlivé účinky $x farmakokinetika $x krev $x aplikace a dávkování $7 D000069604
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a P-glykoproteiny $x genetika $7 D018435
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a ischemická cévní mozková příhoda $x prevence a kontrola $x genetika $x krev $7 D000083242
- 650 12
- $a karboxylesterhydrolasy $x genetika $x krev $7 D002265
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a antitrombiny $x škodlivé účinky $x krev $x farmakokinetika $x aplikace a dávkování $7 D000991
- 650 12
- $a krvácení $x chemicky indukované $x krev $7 D006470
- 650 _2
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a fibrilace síní $x farmakoterapie $x genetika $x komplikace $x krev $7 D001281
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Janský, Petr $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Magerová, Hana $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Šrámková, Tereza $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Kešnerová, Petra $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Kmetonyová, Silvia $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Šulc, Vlastimil $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Halmová, Hana $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Šrámek, Martin $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $u Department of Neurology, Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Šarbochová, Ivana $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Paulasová-Schwabová, Jaroslava $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Benešová, Kateřina $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Macek, Jan $u Pharmakl spol. s.r.o, Prague, Czech Republic; and
- 700 1_
- $a Maťoška, Václav $u Laboratory of Molecular Diagnostics, Hospital Na Homolce, Prague, Czech Republic
- 700 1_
- $a Tomek, Aleš $u Department of Neurology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 773 0_
- $w MED00179772 $t American journal of therapeutics $x 1536-3686 $g Roč. 31, č. 4 (2024), s. e362-e371
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38525959 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110848 $b ABA008
- 999 __
- $a ok $b bmc $g 2202265 $s 1231910
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 31 $c 4 $d e362-e371 $e 20240320 $i 1536-3686 $m American journal of therapeutics $n Am J Ther $x MED00179772
- LZP __
- $a Pubmed-20241015
